All In Biotech

Drug Trial Radar · NCT05970497

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Oct 31, 2023

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Krystal Biotech, Inc.Industry
Sponsor type
Industry
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination with Opdualag to subjects with unresectable or metastatic melanoma. Subjects in dose escalation (Cohorts 1 through 3) and dose expansion (Cohort 4) will receive intratumoral injections of KB707 approximately every three weeks. Cohorts 1 through 4 are closed to new enrollment. Dose expansion Cohort 5 and Cohort 6 will evaluate subjects with advanced melanoma. Subjects in Cohort 5 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Opdualag (dosed every q4w per prescribing information). Subjects in Cohort 6 will receive intratumoral injections of KB707 biweekly (q2w), delivered in combination with Keytruda (dosed every q6w per prescribing information). All subjects will be treated until disease progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.

Conditions

  • Cancer
  • Melanoma Stage III
  • Melanoma Stage IV
  • Cutaneous Melanoma

Interventions

  • KB707Biological

    Genetically modified herpes simplex type 1 virus

  • OpdualagDrug

    Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)

  • KEYTRUDA ®( Pembrolizumab)Drug

    Immunotherapy (PD-1 immune checkpoint inhibitor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of adverse events (AEs)Time frame: up to 36 months
  2. Percentage of serious adverse events (SAEs)Time frame: up to 36 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Health

    Los Angeles, California · Recruiting

  • Mission Dermatology Center

    Rancho Santa Margarita, California · Recruiting

  • BRCR Global

    Weston, Florida · Recruiting

  • IU Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Morristown Medical Center / Atlantic Health System

    Morristown, New Jersey · Recruiting

  • Weill Cornell Medicine-New York-Presbyterian Hospital

    New York, New York · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Renovatio Clinical - El Paso

    El Paso, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Renovatio Clinical - The Woodlands

    The Woodlands, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.